NCT07188103 2025-09-23
Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
Anhui Provincial Hospital
Phase 2 Recruiting
Clinical Trials
12 trialsNCT07046221 2025-07-20
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06692270 2025-02-28
Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT05628610 2024-08-13
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06231680 2024-03-29
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
Phase 2 Unknown
NCT05624099 2023-10-19
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Fujian Cancer Hospital
Phase 2 Recruiting
NCT05007145 2021-12-21
REVO
Fujian Cancer Hospital
Phase 2 Unknown
NCT05013697 2021-08-19
TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
Henan Cancer Hospital
Phase 2 Unknown
NCT03985670 2019-12-12
Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT02924909 2018-03-20
QUIMERA
Instituto Nacional de Cancer, Brazil
Phase 2 Unknown
NCT01843829 2014-03-24
NeoSCOPE
Velindre NHS Trust
Phase 2 Unknown
NCT00453323 2010-07-12
Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer
National Cancer Center, Korea
Phase 2 Unknown